Sumitomo Mitsui Trust Group Inc. lessened its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 0.5% in the 3rd quarter, according to its most recent filing with the SEC.

Teva Pharmaceuticals will pay $450 million to resolve allegations that the generic drug manufacturer submitted false claims and violated a federal law that prohibits the payment of kickbacks to ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday ...

A year ago, Teva agreed to pay $4.3 billion in compensation to settle claims brought against it in the US arising from its involvement in the sale of opioid painkillers, which caused addiction in ...

Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing ...

The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its multiple sclerosis drug and for ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the ...

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International ...

TEVA’s biggest revenue generator in the U.S., its generics segment, added more than $1B to the company's topline in Q2 2024, implying ~16% YoY growth. More on Novartis, Novartis AG, etc.

Phase 3 trial results show Teva's TEV-'749 improves social functioning in adults with schizophrenia without post-injection ...